Prognostic significance of changes of tumor epidermal growth factor receptor expression after neoadjuvant chemoradiation in patients with rectal adenocarcinoma

Strahlentherapie und Onkologie

Volumn 188, Issue 9, 2012, Pages 833-838

  Dvorak, J ^a   Sitorova, V ^a   Ryska, A ^a   Sirak, I ^a   Richter, I ^a,b   Hatlova, J ^a   Ferko, A ^a   Melichar, B ^c   Petera, J ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

^b REGIONAL HOSPITAL LIBEREC   (Czech Republic)

^c PALACKÝ UNIVERSITY   (Czech Republic)

Author keywords

Disease free survival; Epidermal growth factor receptor; Neoadjuvant chemoradiation; Rectal adenocarcinoma; Treatment outcome

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROURACIL;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CHEMORADIOTHERAPY; CONTINUOUS INFUSION; DISEASE FREE SURVIVAL; EXTERNAL BEAM RADIOTHERAPY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; OVERALL SURVIVAL; PROTEIN EXPRESSION; RADIATION DOSE FRACTIONATION; RECTUM BIOPSY; RECTUM CARCINOMA; SURVIVAL TIME;

ADENOCARCINOMA; ADULT; CHEMORADIOTHERAPY, ADJUVANT; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM PROTEINS; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECTAL NEOPLASMS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84866636746     PISSN: 01797158     EISSN: 1439099X     Source Type: Journal    
DOI: 10.1007/s00066-012-0160-x     Document Type: Article

References (36)

1. Akimoto T, Hunter NR, Buchmiller L et al (1999) Inverse relationship between epidermal growth factor receptor expression and radiocurability of murine carcinomas. Clin Cancer Res 5:2884-2890
2. Azria D, Bibeau F, Barbier N et al (2005) Prognostic impact of epidermal growth factor receptor (EGFR) expression on loco-regional recurrence after preoperative radiotherapy in rectal cancer. BMC Cancer 5:62
3. Baumann M, Krause M, Dikomey E et al (2007) EGFR-targeted anti-cancer drugs in radiotherapy: preclinical evaluation of mechanisms. Radiother Oncol 83:238-248
4. Bertolini F, Chiara S, Bengala C et al (2009) Neoadjuvant treatment with single-agent cetuximab followed by 5-FU, cetuximab, and pelvic radiotherapy: a phase II study in locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 73:466-472
5. Bonner JA, Harari PM, Giralt J et al (2006) Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354:567-578
6. Bonner JA, Harari PM, Giralt J et al (2010) Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase three randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 11:21-28
7. Bonner JA, Maihle NJ, Folven BR et al (1994) The interaction of epidermal growth factor and radiation in human head and neck squamous cell carcinoma cell lines with vastly different radiosensitivities. Int J Radiat Oncol Biol Phys 29:243-247
8. Ceelen WP, Van Nieuwenhove Y, Fierens K (2009) Preoperative chemoradiation versus radiation alone for stage II and III resectable rectal cancer. Cochrane Database Syst Rev (1):CD006041
9. Chung KY, Minsky B, Schrag D et al (2006) Phase I trial of preoperative cetuximab with concurrent continuous infusion 5-fluorouracil and pelvic radiation in patients with local-regionally advanced rectal cancer. J Clin Oncol 24(18 suppl):Abstract 3560
10. Cunningham D, Humblet Y, Siena S et al (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351:337-345
11. Dent P, Reardon DB, Park JS et al (1999) Radiation-induced release of transforming growth factor alpha activates the epidermal growth factor receptor and mitogen-activated protein kinase pathway in carcinoma cells, leading to increased proliferation and protection from radiation-induced cell death. Mol Biol Cell 10:2493-2506
12. Douillard JY, Siena S, Cassidy J et al (2010) Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 28:4697-4705
13. Giralt J, las Heras M de, Cerezo L et al (2005) Grupo Espanol de Investigacion Clinica en Oncologia Radioterapica (GICOR): The expression of epidermal growth factor receptor results in a worse prognosis for patients with rectal cancer treated with preoperative radiotherapy: a multicenter, retrospective analysis. Radiother Oncol 74:101-108
14. Glynne-Jones R, Mawdsley S, Harrison M (2011) Antiepidermal growth factor receptor radiosensitizers in rectal cancer. Anticancer Drugs 22:330-340
15. Hofheinz RD, Horisberger K, Woernle C et al (2006) Phase I trial of cetuximab in combination with capecitabine, weekly irinotecan, and radiotherapy as neoadjuvant therapy for rectal cancer. Int J Radiat Oncol Biol Phys 66:1384-1390
16. Horisberger K, Treschl A, Mai S et al (2009) Cetuximab in combination with capecitabine, irinotecan, and radiotherapy for patients with locally advanced rectal cancer: results of a Phase II MARGIT trial. Int J Radiat Oncol Biol Phys 74:1487-1493
17. Kaufman M, Mehrotra B, Limaye S et al (2008) EGFR expression in gallbladder carcinoma in North America. Int J Med Sci 5:285-291
18. Kavanagh BD, Dent P, Schmidt-Ullrich RK et al (1998) Calcium-dependent stimulation of mitogen-activated protein kinase activity in A431 cells by low doses of ionizing radiation. Radiat Res 149:579-587
19. Kim JS, Kim JM, Li S et al (2006) Epidermal growth factor receptor as a predictor of tumor downstaging in locally advanced rectal cancer patients treated with preoperative chemoradiotherapy. Int J Radiat Oncol Biol Phys 66:195-200
20. Li S, Kim JS, Kim JM et al (2006) Epidermal growth factor receptor as a prognostic factor in locally advanced rectal-cancer patients treated with preoperative chemoradiation. Int J Radiat Oncol Biol Phys 65:705-712
21. Liang K, Ang KK, Milas L et al (2003) The epidermal growth factor receptor mediates radioresistance. Int J Radiat Oncol Biol Phys 57:246-254
22. Machiels JP, Sempoux C, Scalliet P et al (2007) Phase I/II study of preoperative cetuximab, capecitabine, and external beam radiotherapy in patients with rectal cancer. Ann Oncol 18:738-744
23. Marquardt F, Rödel F, Capalbo G et al (2009) Molecular targeted treatment and radiation therapy for rectal cancer. Strahlenther Onkol 185:371-378
24. Milas L, Akimoto T, Hunter NR et al (2002) Relationship between cyclin D1 expression and poor radioresponse of murine carcinomas. Int J Radiat Oncol Biol Phys 52:514-521
25. Mishani E, Abourbeh G (2007) Cancer molecular imaging: radionuclide-based biomarkers of the Epidermal Growth Factor Receptor (EGFR). Curr Top Med Chem 7:1755-1772
26. Nasu S, Ang KK, Fan Z et al (2001) C225 antiepidermal growth factor receptor antibody enhances tumor radiocurability. Int J Radiat Oncol Biol Phys 51:474-477
27. Pantaleo MA, Fanti S, Nannini M et al (2008) What oncologists need and require from nuclear medicine. Eur J Nucl Med Mol Imaging 35:1761-1765
28. Peeters M, Price TJ, Cervantes A et al (2010) Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol 28:4706-4713
29. Pinto C, Di Fabio F, Maiello E et al (2011) Phase II study of panitumumab, oxaliplatin, 5-fluorouracil, and concurrent radiotherapy as preoperative treatment in high-risk locally advanced rectal cancer patients (StarPan/STAR-02 Study). Ann Oncol 22:2424-2430
30. Rödel C, Arnold D, Hipp M et al (2008) Phase I-II trial of cetuximab, capecitabine, oxaliplatin, and radiotherapy as preoperative treatment in rectal cancer. Int J Radiat Oncol Biol Phys 70:1081-1086
31. Rödel C, Sauer R (2007) Integration of novel agents into combined-modality treatment for rectal cancer patients. Strahlenther Onkol 183:227-235
32. Sauer R, Becker H, Hohenberger W et al (2004) Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 351:1731-1740
33. Schmidt-Ullrich RK, Mikkelsen RB, Dent P et al (1997) Radiation-induced proliferation of the human A431 squamous carcinoma cells is dependent on EGFR tyrosine phosphorylation. Oncogene 15:1191-1197
34. Van Cutsem E, Köhne CH, Hitre E et al (2009) Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360:1408-1417
35. Van Cutsem E, Peeters M, Siena S et al (2007) Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 25:1658-1664
36. Wadlow RC, Ryan DP (2010) The role of targeted agents in preoperative chemoradiation for rectal cancer. Cancer 116:3537-3548